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Abstract
Background: Over the last years, less invasive surgical techniques with soft tissue preservation for bone conduction
hearing implants (BCHI) have been introduced such as the linear incision technique combined with a punch. Results
using this technique seem favorable in terms of rate of peri-abutment dermatitis (PAD), esthetics, and preservation of skin
sensibility. Recently, a new standardized surgical technique for BCHI placement, the Minimally Invasive Ponto Surgery
(MIPS) technique has been developed by Oticon Medical AB (Askim, Sweden). This technique aims to standardize surgery
by using a novel surgical instrumentation kit and minimize soft tissue trauma.
Methods: A multicenter randomized controlled trial is designed to compare the MIPS technique to the linear incision
technique with soft tissue preservation. The primary investigation center is Maastricht University Medical Center. Sixty-two
participants will be included with a 2-year follow-up period. Parameters are introduced to quantify factors such as loss of
skin sensibility, dehiscence of the skin next to the abutment, skin overgrowth, and cosmetic results. A new type of
sampling method is incorporated to aid in the estimation of complications. To gain further understanding of PAD, swabs
and skin biopsies are collected during follow-up visits for evaluation of the bacterial profile and inflammatory cytokine
expression.
The primary objective of the study is to compare the incidence of PAD during the first 3 months after BCHI placement.
Secondary objectives include the assessment of parameters related to surgery, wound healing, pain, loss of sensibility of
the skin around the implant, implant extrusion rate, implant stability measurements, dehiscence of the skin next to the
abutment, and esthetic appeal. Tertiary objectives include assessment of other factors related to PAD and a health
economic evaluation.
Discussion: This is the first trial to compare the recently developed MIPS technique to the linear incision technique with
soft tissue preservation for BCHI surgery. Newly introduced parameters and sampling method will aid in the prediction of
results and complications after BCHI placement.
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Background
The World Health Organization estimated that approxi-
mately 360 million people worldwide suffer from disab-
ling hearing loss (HL) [1]. People with HL can often
benefit from the use of hearing devices, such as hearing
aids, but patients with, e.g., conductive hearing loss can-
not always profit from traditional hearing aids. In order
to improve hearing for this group of patients, the bone-
anchored hearing aid (BAHA), also known as the bone
conduction hearing implant (BCHI) was introduced in
1981 [2]. The BCHI consists of a titanium fixture im-
planted in the retroauricular bone of the skull with an
abutment that breaches the skin, so that a sound proces-
sor can be attached to it. The sound processor converts
sound waves into vibrations via its transducer. These
vibrations are conducted by the abutment to the titan-
ium fixture and ultimately to the skull. The skull con-
ducts these vibrations to both inner ears, bypassing any
problems in the ear canal or middle ear [3]. BCHIs are
currently considered a suitable treatment option for
three groups of patients, namely patients with conduct-
ive HL, mixed HL or single-sided deafness (SSD).
This technology has been reported to improve the
quality of life for these patients, although the available
data is limited [4, 5]. Recently, measuring quality of life
and wellbeing using the concept of capabilities has
gained more interest [6]. It can be expected that inter-
ventions that entail placing a percutaneous implant to
improve hearing, may influence an individual in more
ways than just solely altering hearing (e.g., the ability to
participate in society versus the perceived disadvantages
of these types of implants such as cosmetic and social
concerns [7, 8]). This perspective will be considered in
this trial as well. Over the years, the BCHI has become
an established treatment option with approximately
200,000 BCHI surgeries worldwide to date [9].
Although successful, the BCHI has complications.
Known problems include skin inflammation, also known
as peri-abutment dermatitis (PAD), pain, numbness of
the skin around the implant, skin overgrowth, and im-
plant loss [10]. PAD is graded on a five-point scale called
the Holgers Index [11] and is perceived as the most
common complication of BCHI use with an estimated
occurrence of 16.1–38.1 % among all recipients [10].
PAD is an inflammatory process that is presumed to be
multifactorial and little is known about the precise
etiology of this condition [12]. Shear stress on the skin
around the abutment [2, 13] sets on as the implant and
abutment combination fixed to the skull is immovable.
This may cause tearing of the skin (e.g., while turning on
a pillow at night or during head and jaw movements).
The implant and abutment are made of titanium, which
may elicit a foreign body response [12, 14]. Also the for-
mation of a biofilm on the abutment by bacteria that
colonize the wound site due to persistent breach of the
skin might play an important role [15, 16]. Another side
effect of the BCHI is pain. This is frequently experienced
by patients [17], however the exact cause for this, some-
times chronic pain, remains unknown [18–20]. Another
condition which has anecdotally been observed is skin
sagging, the presence of excess skin cranially to the abut-
ment [21]. This might be problematic as it can influence
the sound processor coupling and the proper function of
the processor.
Various strategies for reducing complication rates with
BCHIs have been employed throughout the years. Trad-
itionally, the skin surrounding the abutment was
thinned, but van de Berg et al. noted lower complication
rates after BCHI surgery with a less invasive approach
[20]. Since then, an even less invasive, single-stage pro-
cedure, where the soft tissue surrounding the abutment
is left intact [22–25], has become one of the most com-
mon techniques used for BCHI surgery. Advantages of
this tissue-preserving approach include: less surgical
procedure time, reduced numbness or pain and better
cosmetic results [22, 24, 25].
The osteotomy preparation, assuring minimal trauma
to the bone, space to maneuver the burr head, and
adequate cooling of the site as well as minimal trauma
and displacement of the soft tissue, are all important fac-
tors when designing a procedure for installing a bone-
anchored percutaneous implant [26]. Furthermore, to
achieve comparable results across surgeries, the vari-
ation in surgical technique introduced by different sur-
geons needs to be minimized. Based on local clinical
practices and available tools, surgeons in different coun-
tries have started using punch-only surgical techniques
for BCHI surgery [27–29]. The available surgical tools
were not developed for this punch-only approach, pre-
senting potential drawbacks such as soft tissue damage
and insufficient irrigation. In pursuance of developing a
standardized minimally invasive punch-only surgical kit
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and method, Oticon Medical AB (Askim, Sweden)
started the design of instruments for a single-stage BCHI
surgical technique in 2013. The goal of this new Minim-
ally Invasive Ponto Surgery (MIPS) was to optimize tis-
sue preservation, minimize tissue trauma, and provide a
punch-only standardized surgical procedure with stan-
dardized surgical equipment aiming to eliminate surgical
variability [26].
Previous BCHI clinical trials used non-validated out-
come measurement scales, creating a need for validated
alternatives. Most questionnaires and endpoints cur-
rently used to evaluate the BCHI from the perspective of
the clinicians rather than that of the patients’ [30]. We
know that studies using non-validated scales are prone
to risk of bias [31]. In contrast, studies that use reliable,
systematic and validated outcome measures give the
possibility to compare different trials and perform a
meta-analysis [32]. Another limitation is that the num-
ber of prospective randomized controlled trials in the
field is low [22, 33–36]. Moreover, complications related
to the BCHI can vary over time and may be missed by
only assessing patients at fixed time points coinciding
with preplanned trial visits. Important information is lost
this way and incidence numbers might become under-
or overestimated. By not collecting all the information
which is available, the ability to find a difference between
two interventions also decreases. In this clinical trial, the
amount of standard visits is decreased in favor of collect-
ing more information during extra consultations in case
of problems.
The decision to choose one intervention over the
other in a health care system with limited resources
depends on the associated (clinical) benefits, but also
on the incurred additional costs or cost savings. As
reviewed by Crowson et al. [4], only a few investiga-
tions addressed the cost-effectiveness of a BCHI
intervention, resulting in uncertainty regarding cost-
effectiveness. One retrospective study by Monksfield
et al. has been executed in the United Kingdom that
compared gain in quality-adjusted life years to
BCHI-related costs. Costs included: implantation sur-
gery, post-surgical care, the first processor, annual
check-up, processor maintenance, and processor
replacement costs after 3 years [5]. This study concluded
that the BCHI is probably cost-effective. So far, no study
included non-health care costs, such as loss of productiv-
ity, travel costs and out-of-pocket costs.
In this article, we describe the research protocol for a
multicenter randomized controlled study comparing the
new MIPS technique to the linear incision technique
with soft tissue preservation [24, 26] comparing the inci-
dence of inflammation as primary objective. In this trial,
revised parameter scales are introduced to quantify fac-
tors such as loss of skin sensibility, dehiscence of the
skin next to the abutment, skin overgrowth, and cos-
metic results. These are modified to reduce the subject-
ive interpretation and are intended to be validated. For
exploratory outcome measures related to PAD such as
skin biopsies, bacterial swabs are collected. An econom-
ical evaluation is planned with quality of life approached
from a capability perspective as well. The MIPS tech-
nique is hypothesized to result in a lower incidence of
inflammation compared to the linear incision technique
with soft tissue preservation.
Methods
Study design, ethics, setting, and recruitment
This study is a sponsor-initiated multicenter, open, ran-
domized, controlled clinical investigation. This article
has been drafted following SPIRIT guidelines [37] (See
Table 1 in Additional file 1). Three hospitals in the
Netherlands are currently recruiting participants for this
study: Maastricht University Medical Center (MUMC+),
ZiekenhuisGroep Twente (ZGT) and Medisch Centrum
Leeuwarden (MCL). MUMC+ is an academic teaching
hospital. ZGT and MCL are general hospitals. This mul-
ticenter study is performed in accordance with the Dec-
laration of Helsinki [38], has been approved by the ethics
committee of MUMC+ (NL50072.068.14/METC141007)
and has been registered at clinicaltrials.gov (trial number:
NCT02438618). The local ethics committees of ZGT
(Adviescommissie locale uitvoerbaarheid wetenschappelijk
onderzoek) and MCL (Commissie Onderzoeksverklaring)
approved the local execution of this trial. A total of 62 par-
ticipants will be recruited at the ear, nose and throat out-
patient departments by the (local) researchers. Patients are
considered eligible for participation [22, 39] (I) if they will
undergo unilateral BCHI surgery and (II) when they
are ≥ 18 years of age. Participants will be excluded
from participation in case of (I) a history of immuno-
suppressive disease, (II) usage of systemic immuno-
suppressive medication, (III) bilateral BCHI placement,
(IV) relevant dermatological disease (e.g., psoriasis, severe
eczema), (V) participation in other studies, and (VI) when
no suitable site for a 4-mm-wide implantation during sur-
gery is found. For inclusion, written informed consent will
be provided from all participants (See Additional file 2).
Study interventions and allocation
All participants will undergo single-stage surgery to
receive a 4-mm Ponto wide implant with mounted abut-
ment (Oticon Medical AB, Askim, Sweden), which will
be performed by an experienced ENT surgeon. Four
abutment lengths are available: 6, 9, 12 and 14 mm. Sub-
jects will be randomized to the test group (MIPS tech-
nique [26]) or the control group (linear incision
technique with soft tissue preservation [24]) in the order
in which they enter the study. Skin thickness is a
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Table 1 Schedule of enrolment, interventions, and assessments
Follow-up visits are planned post-surgery. Pain assessment: score for pain around the implant; radiating pain; headache associated with implant. Cosmetic result
scores: score for natural skin position, baldness, scarring, skin color, indentation, overall cosmetic score. Light gray chart indicates measurements assessed at
follow-up visits/extra consultations with a Holgers Index score ≥ 2
RFA:ISQ Resonance Frequency Analysis: Implant Stability Quotient, HUI3 Health Utilities Index Mark 3, APHAB Abbreviated Profile of Hearing Aid Benefit, ICECAP-A
ICEpop CAPability measure for Adults, N.A. not applicable, IS-pro a 16S-23S rDNA interspace (IS) region-based profiling method
*Outcome measurements obtained at Maastricht University Medical Center only
ˇOnly after explicit additional informed consent
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possible factor that could influence inflammation, but
this is measured during surgery, making it impossible to
stratify for skin thickness prior to surgery. Considering
that men are known to have significantly thicker skin
than women [40], group allocation is stratified for gen-
der. Researchers will randomize each subject using
randomization software (Statistiska Konsultgruppen,
Gothenburg, Sweden), which will be performed in each
research center independently in a 1:1 ratio for the test
and control group stratified for gender until the total
number of 62 participants has been reached. Due to
clear differences in surgical techniques, it is impossible
to blind the surgeon, researcher or subject. In short both
surgical techniques are described here:
Control group (linear incision technique with soft tissue
preservation) [24, 41]
The intended implant position is marked (Fig. 1a). (I)
A retroauricular linear incision is made down to the
periosteum that is subsequently opened to expose the
periosteum posterior to the incision line (Fig. 1b). (II)
At the intended implant site, a central area of perios-
teum is removed. (III) An initial 3-mm-deep hole is
created using a guide drill. (IV) If there is still bone
at the bottom of the initial hole, it is deepened to 4
mm using the same drill by removing a spacer. (V)
To prepare the initial hole for implant insertion it is
widened with a countersink drill. (VI) The implant
with mounted abutment is installed with a torque set-
ting of 40–50 Ncm. (VII) The skin is retracted over
the abutment and dermal sutures are placed. (VIII)
The abutment is recovered by punching the skin with
a 5-mm punch. (IX) A healing cap is attached to the
abutment and gauze drenched in an antibiotic oint-
ment is applied.
Test group (MIPS technique) [26, 42]
The intended implant position is marked (Fig. 1a). (I) An
incision is created with a 5-mm punch at the intended
implant site (Fig. 1c). (II) The periosteum and remaining
soft tissue around the incision hole are removed with a
raspatorium. (III) The cannula is inserted at the surgical
site. (IV) A 3-mm hole is created initially with the can-
nula guide drill. (V) If there is bone at the bottom of the
3-mm hole, it is deepened to 4 mm using the same drill
by removing a spacer. (VI) To prepare the initial hole for
implant insertion, it is widened with the cannula widen-
ing drill. (VII) The cannula is removed and subsequently
the implant with mounted abutment is installed with a
torque setting of 40–50 Ncm. (VIII) To help estimate
complete insertion of the implant, an installation indica-
tor is attached to the abutment inserter, which makes it
possible for the surgeon to count the number of rota-
tions. This step was added during the course of the
study. (IX) A healing cap is attached to the abutment
and gauze drenched in an antibiotic ointment is applied.
Follow-up
Follow-up visits for all participants are scheduled at 9
days, 21 days, 3 months, 1 year and 2 years post-surgery
(Fig. 2). During this period all extra consultations are
captured in high detail. The consultations are largely
comparable to standard visits (Table 1). By compiling
extra consultation visits and regular follow-up visits, we
can present a more accurate estimate of common com-
plications that can occur at any time point.
Outcomes
Primary outcome
The primary outcome of this study is the incidence of
inflammation (episodes of PAD) between surgery and 3
months post-surgery. During each visit, the peri-abutment
Fig. 1 Surgical implantation techniques. a Implant positioning. b Schematic presentation of the linear incision technique with soft tissue preservation.
(I) Linear incision. (II) Opening of skin. (III) Initial hole drilling. (IV) Countersink drilling. (V) Eccentric skin punch to uncover abutment. (VI) Result. c
Schematic presentation of Minimally Invasive Ponto Surgery (MIPS) technique. (I) Incision hole. (II) Removal of periost and soft tissue. (III) Placement of
cannula. (IV) Drilling procedure (cannula guide drill and cannula widening drill). (V) Implant placement with the insertion indicator. (VI) Result
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skin is graded based on the Holgers Index. The Holgers
Index is a five-point scale described by Holgers [11]: “0 no
irritation; 1 slight redness; 2 red and slightly moist tissue,
no granuloma formation; 3 reddish and moist; sometimes
granulation tissue; 4 removal of skin-penetrating implant
necessary due to infection” [11]. In this study, inflamma-
tion has been defined as the occurrence of a Holgers
Index ≥ 2 as this often requires substantial treatment
(e.g., systemic antibiotics or local intervention).
Secondary outcomes
Secondary outcomes include surgical procedure time,
wound healing, presence of dehiscence after surgery, soft
tissue height, loss of skin sensibility, pain, cosmetic
results, implant stability quotient (ISQ) values, and
extrusion rate (Table 1).
Surgical procedure time consists of the length of sur-
gery (from the incision until the placement of the heal-
ing cap) and the total time spent in the operating
theater by the subject (entering theater until leaving
theater) in minutes. Both timings are measured using a
stopwatch and are included because the preparation and
post-surgical care can differ. Wound healing is evaluated
during standard follow-up visits and can be graded as
complete, partial or incomplete. The presence of dehis-
cence is evaluated at all visits. Soft tissue height and
overgrowth is assessed by measuring the distance from
the top of the abutment to the skin in four quadrants.
Numbness is measured as the start of sensibility from
the abutment to the most outward diameter. Pain is
assessed for three separate domains including pain dir-
ectly around the abutment, radiating pain, and headache
that is related to the BCHI. Pain is graded in a 10-point
scale with a scale of 0 representing “no pain” to 10
representing “the worst pain imaginable”. Cosmetic
results are assessed by the surgeon using several proper-
ties which were thought to be influenced by the surgical
technique. These included the folding of the skin around
the abutment, baldness, scarring, skin color, indentation,
and an overall cosmetic score as assessed by the surgeon
and subject. All results are graded on a 10-point scale
and compared to the contralateral side if applicable. ISQ
values are obtained with the Ostell ISQ equipment
(Ostell, Gothenburg, Sweden) by mounting a Smartpeg
Type 55 on the abutment and obtaining two perpendicu-
lar ISQ values at all visits. All cases of abutment
exchanges and implant extrusion are noted (time of ex-
trusion, reason if known and subsequent action).
Tertiary outcomes
Quality of life and economic evaluation Three ques-
tionnaires are used to evaluate the impact on hearing-
specific and generic quality of life and capabilities. The
questionnaires are filled in at baseline, at 1-year follow-
Fig. 2 Study design and study flow chart
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up, and at 2-year follow-up. The Abbreviated Profile of
Hearing Aid Benefit (APHAB) is a 24-item self-
assessment, disability-based inventory, designed for
hearing-related quality of life [43]. Each item is assessed
in both the unaided and aided situation. The Health
Utilities Index Mark 3 (HUI3) is a preference-based sys-
tem for measuring generic health-related quality of life,
consisting of 17 questions [44]. It provides descriptive
evidence on multiple dimensions of health status, in-
cluding overall health and several health dimensions.
These dimensions include: vision, hearing, speech, am-
bulation/mobility, pain, dexterity, self-care, emotion, and
cognition. Each dimension has three to six discrimin-
atory levels, making it sensitive to health changes in-
duced by interventions [45]. The ICEpop CAPability
measure for Adults (ICECAP-A) was designed [46] to
measure capabilities [47]. Capabilities represent the
“freedom” of an individual to “achieve” a certain func-
tioning, without the need to have actually achieved this
[48]. This 5-point questionnaire has been translated and
validated in Dutch [49]. It specifically assesses the
capabilities attachment, security, enjoyment, role, and
control. These questions include aspects such as inde-
pendence, dignity, comfort, and social interaction, which
might be influenced by hearing loss and subsequent in-
terventions. A last tertiary objective of this study is a full
economical evaluation after data has been collected for 1
year as we assume that 1 year after surgery, the compli-
cation rate, benefits, satisfaction, and BCHI processor
usage are stable in both treatment groups. Cost will be
identified at each study visit using the case report form
(CRF), which is designed to identify costs. We will per-
form a cost-utility analysis, with the quality-adjusted life
year calculated from the obtained HUI3 scores as the
outcome. The analysis will be executed using a societal
perspective. The evaluation will be performed according
to the standards and guidelines of the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) [50].
Exploratory outcomes
Skin displacement High-resolution photographs (MUMC
+: Nikon D800E, Nikon Corp., Tokyo, Japan) with an
additional lens (Nikon AF-S VR Micro-Nikkon 105 mm
f/2.8G IF-ED, Nikon Corp., Tokyo, Japan); ZGT and
MCL: iPhone 6 (Apple Inc., Cupertino, CA, USA) are
collected at surgery and follow-up visits. These photo-
graphs can be used to evaluate the peri-abutment skin
over time and to assess the skin movability in relation to
movements of the head and jaw using standardized skin
markings. These photographs will also be used to study
the validity of the Holgers Index and to investigate peri--
abutment dermatitis. In addition, the minimal and
maximal size of the gap between the abutment and skin
is measured in all quadrants.
Etiology of peri-abutment dermatitis These outcome
measures are obtained at MUMC+ only. Skin biopsies of
the implantation site are obtained during surgery, at 3
months post-surgery, and during episodes of inflamma-
tion if participants have explicitly provided an additional
written informed consent for this procedure. RNA will
be extracted from the biopsies and subsequently cDNA
will be synthesized. We intend to determine mRNA
expression of 15 selected genes (Table 2) using real-
time reverse transcription polymerase chain reaction.
Pre-surgical mRNA expression (baseline) and post-
surgical expression will be compared. Specific profiles re-
lated to inflammatory responses, tissue remodeling,
vascularization, and bacterial infection will be assessed.
Bacterial swabs of the abutment, peri-abutment skin and
contralateral skin are collected during the same time
points. The bacterial content will be evaluated with IS-
pro, a novel 16S-23S rDNA interspace (IS) region-based
profiling method [51]. This method is devised to enable
high-throughput molecular profiling of any microbiota.
The combined data sets will be used to study peri-
abutment dermatitis and validate the Holgers Index.
Analysis
Sample size calculation
The incidence of inflammation, a Holgers Index ≥ 2,
between surgery and 3 months post-surgery will be com-
pared between both groups. The sample size is calcu-
lated using the concept of effect size (ES) as presented
by Lerman and Cohen [52, 53]. The proposed test con-
cerns a two-sample test for binomial proportions, which
is equivalent to a Yates corrected chi-square test for a
2 × 2 contingency table. When taking into account a type
1 error level (α) of 0.05 and a power (1-β) of 0.8, the re-
quired sample size per group is: n = 2(zα + zβ)2/ES 2 =
2(1.65 + 0.84)2/ES2 = 12.4/ES2. Assuming an ES index of
Table 2 Overview of cytokines




IL-6 Tissue remodeling TLR-4
IL-8 MMP-9
TNF-α TIMP-1 Vascularization
IL-17 COL1 α1 VEGF-A
IL-10 FGF-2
IL interleukin, TNF-α tumor necrosis factor alpha, TGF-ß transforming growth
factor beta, MIP-1 α macrophage inflammatory protein 1 alpha, MMP-9 matrix
metalloproteinase 9, TIMP-1 tissue inhibitor of metalloproteinase 1, COL1 α1
collagen, type 1, alpha 1, TLR Toll-like receptor, VEGF-A vascular endothelial
growth factor A, FGF-2 basic fibroblast growth factor-2
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medium to large with ‘h’ of 0.65 to discriminate between
two proportions, the sample size is: n = 12.4/h2 = 12.4/
0.652 = 29.4. With an expected 5 % drop-out rate, 31 par-
ticipants are needed per group, resulting in a total sample
size of 62 participants.
Statistical analysis
This study is designed to include several endpoints
including short-term results (3 months follow-up), long-
term results (2 years follow-up), and an economic evalu-
ation. Short-term results will be evaluated after all
participants have reached 3 months follow-up and will
describe the primary endpoint and secondary endpoints
between surgery and 3 months follow-up. The primary
endpoint will be described by comparing the proportions
of inflammation between surgery and 3 months follow-
up using a chi-square test. Long-term results will also be
used for the economic analysis. Prior to analysis, a statis-
tical analysis plan (SAP) will be created describing the
method of analysis specifically for each endpoint.
Safety
Cases of adverse events or device deficiencies will be
recorded in the CRF. All cases of serious adverse events
(SAE) will be recorded in the corresponding CRF as well
and subsequently reported to the sponsor and respon-
sible regulatory committees. The recorded events will be
incorporated in the applicable study results.
Study management, oversight and publication
The study is monitored by Oticon Medical AB in con-
junction with TFS (Zaltbommel, The Netherlands). Due
to the low risk classification of the investigated proce-
dures, a data monitoring committee was not deemed ne-
cessary. Data handling will conform to Dutch legislation.
Source data is contained in the original records (the
electronic patient dossier), original forms (question-
naires), and CRF. Data will be kept for 15 years. A data
management team, consisting of the principal investiga-
tor, researchers from the coordinating center, and repre-
sentatives from the sponsor are established to oversee
and manage data collection. Any collected human tissue
will be adequately disposed of after analysis. Insurances
are provided for all participants in accordance with
Dutch legislation. Regular care will continue if a subject
has finished follow-up or if a participant withdraws from
the study. The results of this study will be submitted to
peer-reviewed journals without any publication restric-
tions by the sponsor.
Protocol amendments
After initial approval (protocol version 1.2 dated 4
November 2014), the study site opened for accrual on 1
December 2014. So far, the ethics committee has approved
two substantial amendments to the study protocol. In
June 2015, an amendment (protocol version 1.4 12 May
2015) was approved to increase the total number of par-
ticipants from 42 to 62, resulting in a decrease of the ES
from 0.8 to 0.65 with 80 % power to discriminate between
two proportions. In the same amendment, in order to in-
clude sufficient participants, the study was expanded from
a single-center study to a multicenter study. In October
2015, the second amendment (protocol version 1.5 11 Au-
gust 2015) was approved to include MIPS surgical equip-
ment update, based on feedback after the first surgeries.
The alterations in MIPS surgical package included short-
ening of the cannula and the addition of wings in order to
increase the grip and stability of the cannula. The guide
drill was also modified, resulting in a wider drilling hole
making it easier to manually feel the drilling hole with the
widening drill. An installation indicator was also devel-
oped, to assist in visual feedback for insertion complete-
ness by counting the number of rotations during
insertion. These updates were incorporated as MIPS be-
came available to multiple centers around the world and
surgeons provided feedback in relation to their individual
outcomes. These updates are not expected to affect the
primary endpoint in a significant way, hence no
change in the number of participants was necessary
for this amendment. The change in the surgical pro-
cedure might influence secondary outcome measures
(e.g., surgery time, risks on complications such as in-
complete insertion) to a limited extent. All MIPS sur-
geries will be analyzed as one pooled treatment group
but the number of participants per MIPS version will
be reported on.
Discussion
In the design of this prospective multicenter trial, a total
of 62 participants are intended to be included and
followed for a period of 2 years. In this trial, the MIPS
procedure (designed to reduce tissue trauma, standardize
surgery, and alleviate the need for an incisional scar [26])
is compared to the soft tissue preservation technique
[23, 24], which can be regarded as the conventional
method. The incidence of PAD (Holgers Index ≥ 2) be-
tween surgery and 3 months follow-up is the primary out-
come measurement. Adapted measures scales describing
loss of skin sensibility, cosmetic results, and skin height
are introduced. Additionally, various exploratory measure-
ments including skin biopsies, bacterial profile, and skin
movement are incorporated in this study. This exploratory
data might allow conducting of correlative and compara-
tive analyses between the onset of PAD, a changed gene
expression, and the presence of different bacterial species.
This might help in understanding the multifactorial role
bacteria, the immune response, and skin movements play
in the etiology of PAD.
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One of the objectives of this investigation is to collect
biopsies and photographs to explore the incidences of
inflammation. The latter will also be used to validate the
Holgers Index or, if that is not achieved, to create a new
scale for which an internal validation will then be avail-
able. Newly introduced outcome measures such as loss
of sensibility, cosmetic outcomes, pocket size, skin
height, and skin sagging have not yet been validated.
These scales are designed to include as little as possible
subjective interpretation (e.g., using millimeters and pre-
defined quadrants). Also because every subject will be
photographed at every visit, the interpretation of the
Holgers Index score can be justified post hoc and the
validity can be further investigated in the future.
Another important aspect this study addresses is the
timing and frequency of relevant information sampling.
The occurrence of complications may be missed while
following the standardized time points (e.g., patients do
not only show infections at predetermined visits). Vari-
able sampling over time will possibly allow for a more
accurate assessment of the duration and incidences of
complications such as PAD, sensibility loss, and pain
over time. The use of areas under the curve (AUC) is
proposed here as a solution for incorporating informa-
tion available from these extra consultations. We assume
that and encourage participants to visit their ENT
surgeon if they experience a complication (e.g.,
inflammation or pain). By incorporating episodes of
complications, the complication and its burden can be
assessed over time. This approach has been estimated to
result in an increased power without having to increase
subject numbers. In addition, a more accurate representa-
tion of complications over time can possibly be achieved.
Besides conventional and hearing-specific quality-of-
life approaches (e.g., HUI3 and APHAB) this study also
uses the ICECAP questionnaire that focuses on the well-
being of a participant in a broad perspective. In the field
of BCHI and related technologies, it is plausible that in-
terventions have more benefits than just health gains or
hearing improvements. These devices and interventions
might also increase the autonomy, freedom to achieve or
develop, and impact on social interaction. These factors
are important in the perspective of a person as a whole
[54–56] and are currently overlooked by most question-
naires. Potentially, these factors may be playing an im-
portant role in cost-utility or effectiveness. Moreover,
BCHI recipients consist of a diverse complex population
that might broadly differ in experienced benefit (e.g.,
SSD subjects [57]). Arguably, it might turn out that the
ICECAP adds an important new dimension to consider
with the availability of transcutaneous solutions as well.
This might add a new perspective to the current com-
plexity of the decision-making process surrounding
BCHI placement (many different device choices with
highly different profiles), reimbursement policies, com-
plications, and patient preferences.
Limitations
Due to the differences in surgical procedures it is impos-
sible to perform a blinded trial. The surgical wound cre-
ated is evident for the allocated intervention to the
clinician and the patient. The new intervention could
potentially lead to unexpected events, as both the surgi-
cal approach and surgical tools have been modified ex-
tensively. To identify possible issues, (serious) adverse
events will be qualitatively assessed to allow for a correct
identification of differences and potential drawbacks. Al-
though several methods have been implemented to
maximize the collection of information on trial partici-
pants to increase the power of this trial, the small sam-
ple size in this study remains to be a major drawback.
Trial status
Recruitment started in December 2014 and is currently
still ongoing. The predicted study completion date is
August 2018. Short-term results are expected in the last
quarter of 2016.
Additional files
Additional file 1: SPIRIT checklist. (PDF 76 kb)
Additional file 2: Subject information. (PDF 159 kb)
Abbreviations
APHAB: Abbreviated profile of hearing aid benefit; AUC: Area under the
curve; BAHA: Bone-anchored hearing aid; BCHI: Bone conduction hearing
implant; CRF: Case report form ES effect size; HL: Hearing loss; HUI3: Health
utilities index mark 3; ICECAP-A: ICEpop CAPability measure for adults;
ISQ: Implant stability quotient; MCL: Medisch centrum Leeuwarden;
MIPS: Minimally Invasive Ponto Surgery; MUMC+: Maastricht University
Medical Center; PAD: Peri-abutment dermatitis; SAE: Serious adverse event;




This study is financially supported by a research grant from the sponsor,
Oticon Medical AB (Askim, Sweden).
Availability of data and materials
Not applicable.
Authors’ contributions
TC is involved in the execution, coordination and analysis of the study. MvH
is involved in the protocol design, execution, coordination, and analysis of
the study. TC and MvH drafted the first version of the manuscript. HvdB is
involved in study execution and coordination at MCL. AdB is involved in the
study execution and coordination at ZGT. JvT is involved in the execution of
the study at MUMC. JRH is involved in the execution of the study at MUMC.
JWB is involved in the execution of the study at MUMC. MLJ is involved in
the study design, coordination, and analysis. SJ is involved in the study
design, coordination and analysis. MH was involved in the study design. MAJ
is involved in the design and analysis of the study. MJ is involved in the
design and analysis of the study. LA is involved in the design and analysis of
Calon et al. Trials  (2016) 17:540 Page 9 of 11
the study. RS is involved in the design, execution, coordination, and analysis
of the study. All authors read and approved the final manuscript.
Competing interests
TC, MvH and RS are supported with a research grant from Oticon Medical
AB. MLJ and SJ are employed at Oticon Medical AB. MH was formerly
employed at Oticon Medical AB. MvH and RS have previously received a




Ethics approval and consent to participate
This multicenter study has been approved by the ethics committee of
MUMC+ (Medisch-ethische toetsingscommissie azM/UM) (NL50072.068.14/
METC141007). The local ethics committees of ZGT (Adviescommissie locale
uitvoerbaarheid wetenschappelijk onderzoek) and MCL (Commissie
Onderzoeksverklaring) approved the local execution of this trial. For
inclusion, written informed consent will be provided from all participants.
Author details
1Department of Otorhinolaryngology, Head and Neck Surgery, Maastricht
University Medical Center, Maastricht, The Netherlands. 2Department of
Otorhinolaryngology, Medisch Centrum Leeuwarden, Leeuwarden, The
Netherlands. 3Department of Otorhinolaryngology, ZiekenhuisGroep Twente,
Almelo, The Netherlands. 4Oticon Medical AB, Askim, Sweden. 5Department
of Methodology and Statistics, School for Public Health and Primary Care
(CAPHRI), Maastricht University, Maastricht, The Netherlands. 6Department of
Clinical Epidemiology and Medical Technology Assessment (KEMTA),
Maastricht University Medical Centre, Maastricht, The Netherlands.
7Department of Biomaterials, Institute of Clinical Sciences, Sahlgrenska
Academy, University of Gothenburg, Gothenburg, Sweden.
Received: 22 July 2016 Accepted: 16 October 2016
References
1. World Health Organization. WHO global estimates on prevalence of hearing loss.
2012. www.who.int/pbd/deafness/WHO_GE_HL.pdf. Accessed 1 May 2016.
2. Tjellström A, Lindström J, Hallén O, Albrektsson T, Brånemark PI.
Osseointegrated titanium implants in the temporal bone. A clinical study on
bone-anchored hearing aids. Am J Otol. 1981;2:304–10.
3. Stenfelt S, Goode RL. Bone-conducted sound: physiological and clinical
aspects. Otol Neurotol. 2005;26:1245–61.
4. Crowson MG, Tucci DL. Mini review of the cost-effectiveness of unilateral
osseointegrated implants in adults: possibly cost-effective for the correct
indication. Audiol Neurootol. 2016;21:69–71.
5. Monksfield P, Jowett S, Reid A, Proops D. Cost-effectiveness analysis of the
bone-anchored hearing device. Otol Neurotol. 2011;32:1192–7.
6. Verkerk MA, Busschbach JJ, Karssing ED. Health-related quality of life
research and the capability approach of Amartya Sen. Qual Life Res. 2001;10:
49–55.
7. Zawawi F, Kabbach G, Lallemand M, Daniel SJ. Bone-anchored hearing aid:
why do some patients refuse it? Int J Pediatr Otorhinolaryngol.
2014;78:232–4.
8. Siau D, Dhillon B, Andrews R, Green KMJ. Bone-anchored hearing aids and
unilateral sensorineural hearing loss: why do patients reject them? J
Laryngol Otol. 2015;129:321–5.
9. Tjellström A. The father of Osseointegration and the godfather of the BAHA:
Professor Per-Ingvar Brånemark, Göteborg Sweden has passed away in his
86th year. Eur Arch Otorhinolaryngol. 2015;272:779–80.
10. Kiringoda R, Lustig LR. A meta-analysis of the complications associated with
osseointegrated hearing aids. Otol Neurotol. 2013;34:790–4.
11. Holgers KM, Tjellström A, Bjursten LM, Erlandsson BE. Soft tissue reactions
around percutaneuous implants: a clinical study of soft tissue conditions
around skin-penetrating titanuium implants for bone-anchored hearing aids.
Otol Neurotol. 1988;9:56–63.
12. Tjellström A. Percutaneous implants in clinical practice. CRC Crit Rev
Biocompat. 1985;1:205–28.
13. Holt BM, Bachus KN, Beck JP, Bloebaum RD, Jeyapalina S. Immediate post-
implantation skin immobilization decreases skin regression around
percutaneous osseointegrated prosthetic implant systems. J Biomed Mater
Res A. 2013;101:2075–82.
14. Anderson JM, Rodriquez A, Chang DT. Foreign body reaction to
biomaterials. Semin Immunol. 2008;20:86–100.
15. Monksfield P, Chapple ILC, Matthews JB, Grant MM, Addison O, Reid AP, et
al. Biofilm formation on bone-anchored hearing aids. J Laryngol Otol. 2011;
125:1125–30.
16. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS.
2013;121(s136):1–58.
17. Singam S, Williams R, Saxby C, Houlihan FP. Percutaneous bone-anchored
hearing implant surgery without soft-tissue reduction: up to 42 months of
follow-up. Otol Neurotol. 2014;35:1596–600.
18. Mylanus EAM, Johansson CB, Cremers CWRJ. Craniofacial titanium implants
and chronic pain: histologic findings. Otol Neurotol. 2002;23:920–5.
19. Hobson JC, Roper AJ, Andrew R, Rothera MP, Hill P, Green KM.
Complications of bone-anchored hearing aid implantation. J Laryngol Otol.
2010;124:132–6.
20. van de Berg R, Stokroos RJ, Hof JR, Chenault MN. Bone-anchored hearing
aid: a comparison of surgical techniques. Otol Neurotol. 2010;31:129–35.
21. Hagr A. BAHA: bone-anchored hearing aid. Int J Health Sci. 2007;1:265–76.
22. den Besten CA, Bosman AJ, Nelissen RC, Mylanus EAM, Hol MK. Controlled
clinical trial on bone-anchored hearing implants and a surgical technique
with soft tissue preservation. Otol Neurotol. 2016;37:504–12.
23. Hultcrantz M, Lanis A. A five-year follow-up on the osseointegration of
bone-anchored hearing device implantation without tissue reduction. Otol
Neurotol. 2014;35:1480–5.
24. Hultcrantz M. Outcome of the bone-anchored hearing aid procedure without
skin thinning: a prospective clinical trial. Otol Neurotol. 2011;32:1134–9.
25. Verheij E, Bezdjian A, Grolman W, Thomeer HG. A systematic review on
complications of tissue preservation surgical techniques in percutaneous
bone conduction hearing devices. Otol Neurotol. 2016;37:829–37.
26. Johansson M, Holmberg M. Design and clinical evaluation of MIPS – a
new perspective on tissue preservation. White Pap. Oticon Medical,
Askim, Sweden, 2015 October, Rep. No. M524252. doi:10.13140/RG.2.1.
3624.7762.
27. Dumon T, Medina M, Sperling NM. Punch and drill: implantation of bone
anchored hearing device through a minimal skin punch incision versus
implantation with dermatome and soft tissue reduction. Ann Otol Rhinol
Laryngol. 2015;125:199–206.
28. Gordon SA, Coelho DH. Minimally invasive surgery for osseointegrated
auditory implants: a comparison of linear versus punch techniques.
Otolaryngol Head Neck Surg. 2015;152:1089–93.
29. Goldman RA, Georgolios A, Shaia WT. The punch method for bone-
anchored hearing aid placement. Otolaryngol Head Neck Surg. 2013;148:
878–80.
30. Tysome JR, Hill-Feltham P, Hodgetts WE, McKinnon BJ, Monksfield P,
Sockalingham R, et al. The Auditory Rehabilitation Outcomes Network: an
international initiative to develop core sets of patient-centred outcome
measures to assess interventions for hearing loss. Clin Otolaryngol.
2015;40(6):512–5.
31. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;
176:249–52.
32. Barker F, MacKenzie E, Elliott L, de Lusignan S. Outcome measurement in
adult auditory rehabilitation: a scoping review of measures used in
randomized controlled trials. Ear Hear. 2015;36:567–73.
33. Høgsbro M, Agger A, Johansen LV. Successful loading of a bone-
anchored hearing implant at two weeks after surgery: randomized trial
of two surgical methods and detailed stability measurements. Otol
Neurotol. 2015;36:e51–7.
34. Nelissen RC, Stalfors J, de Wolf MJ, Flynn MC, Wigren S, Eeg-Olofsson M, et al.
Long-term stability, survival, and tolerability of a novel osseointegrated implant
for bone conduction hearing: 3-year data from a multicenter, randomized,
controlled, clinical investigation. Otol Neurotol. 2014;35:1486–91.
35. Nelissen RC, den Besten CA, Mylanus EAM, Hol MK. Stability, survival, and
tolerability of a 4.5-mm-wide bone-anchored hearing implant: 6-month data
from a randomized controlled clinical trial. Eur Arch Otorhinolaryngol.
2016;273:105–11.
Calon et al. Trials  (2016) 17:540 Page 10 of 11
36. Dun CA, de Wolf MJ, Hol MK, Wigren S, Eeg-Olofsson M, Green K, et al.
Stability, survival, and tolerability of a novel baha implant system: six-month
data from a multicenter clinical investigation. Otol Neurotol. 2011;32:1001–7.
37. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K,
Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ. SPIRIT 2013
statement: defining standard protocol items for clinical trials. Ann Intern
Med. 2013;158:200–7.
38. World Medical Association. World Medical Association Declaration of
Helsinki: ethical principles for medical research involving human subjects.
Bull World Health Organ. 2001;79(4):373.
39. Faber HT, Dun CA, Nelissen RC, Mylanus EAM, Cremers CW, Hol MK. Bone-
anchored hearing implant loading at 3 weeks: stability and tolerability after
6 months. Otol Neurotol. 2013;34:104–10.
40. Sandby-Møller J, Poulsen T, Wulf HC. Epidermal thickness at different body
sites: relationship to age, gender, pigmentation, blood content, skin type
and smoking habits. Acta Derm Venereol. 2003;83:410–3.
41. Oticon Medical AB. Surgical manual including linear incision with tissue
preservation, M52058INT/ 2015.06. 2015. http://www.oticonmedical.com/~
asset/cache.ashx?id=42139&type=14&format=web. Accessed 1 June 2016.
42. Oticon Medical AB. Addendum to surgical manual including Minimally
Invasive Ponto Surgery (MIPS), M52188INT/2015.06. 2015. http://www.
oticonmedical.com/~asset/cache.ashx?id=43115&type=14&format=web.
Accessed 7 November 2016.
43. Cox RM, Alexander GC. The abbreviated profile of hearing aid benefit. Ear
Hear. 1995;16:176–86.
44. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status
classification systems. Health Utilities Index. Pharmacoeconomics. 1995;7:490–502.
45. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI):
concepts, measurement properties and applications. Health Qual Life
Outcomes. 2003;1:54.
46. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of
capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21:167–76.
47. Sen A. Development as freedom. Oxford: Oxford University Press; 2001.
48. Al-Janabi H, Peters TJ, Brazier J, Bryan S, Flynn TN, Clemens S, et al. An
investigation of the construct validity of the ICECAP-a capability measure.
Qual Life Res. 2013;22:1831–40.
49. van Hoof M, Jeuring SF, Stokroos RJ, Joore MA. A new perspective on
measuring quality of life using the capability approach. Ned Tijdschr
Geneeskd. 2015;159:A9234.
50. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al.
Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good
Research Practices Task Force Report. Value Health. 2015;18:161–72.
51. Budding AE, Grasman ME, Lin F, Bogaards JA, Soeltan-Kaersenhout DJ,
Vandenbroucke-Grauls CM, et al. IS-pro: high-throughput molecular
fingerprinting of the intestinal microbiota. FASEB J. 2010;24:4556–64.
52. Cohen J. Quantitative methods in psychology. Nature. 1938;141:613.
53. Lerman J. Study design in clinical research: sample size estimation and
power analysis. Can J Anaesth. 1996;43:184–91.
54. Law I, Widdows H. Conceptualising health: insights from the capability
approach. Heal Care Anal. 2008;16:303–14.
55. Ruger JP. Health capability: conceptualization and operationalization. Am J
Public Health. 2010;100:41–9.
56. Marfeo EE, Haley SM, Jette AM, Eisen SV, Ni P, Bogusz K, Meterko M,
McDonough CM, Chan L, Brandt DE, Rasch EK. Conceptual foundation for
measures of physical function and behavioral health function for social
security work disability evaluation. Arch Phys Med Rehabil. 2013;94:1645–52.
57. Faber HT, Nelissen RC, Kramer SE, Cremers CW, Snik AF, Hol MK. Bone-
anchored hearing implants in single-sided deafness patients: long-term use
and satisfaction by gender. Laryngoscope. 2015;125:2790–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Calon et al. Trials  (2016) 17:540 Page 11 of 11
